Tolerability of paroxetine in Parkinson's disease: A prospective study
Identifieur interne : 002A02 ( Main/Corpus ); précédent : 002A01; suivant : 002A03Tolerability of paroxetine in Parkinson's disease: A prospective study
Auteurs : Silvana Tesei ; Angelo Antonini ; Margherita Canesi ; Anna Zecchinelli ; Claudio B. Mariani ; Gianni PezzoliSource :
- Movement Disorders [ 0885-3185 ] ; 2000-09.
English descriptors
- KwdEn :
Abstract
Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.
Url:
DOI: 10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I
Links to Exploration step
ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mariani, Claudio B" sort="Mariani, Claudio B" uniqKey="Mariani C" first="Claudio B." last="Mariani">Claudio B. Mariani</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</idno><idno type="url">https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002A02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title><author><name sortKey="Tesei, Silvana" sort="Tesei, Silvana" uniqKey="Tesei S" first="Silvana" last="Tesei">Silvana Tesei</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Antonini, Angelo" sort="Antonini, Angelo" uniqKey="Antonini A" first="Angelo" last="Antonini">Angelo Antonini</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Canesi, Margherita" sort="Canesi, Margherita" uniqKey="Canesi M" first="Margherita" last="Canesi">Margherita Canesi</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Zecchinelli, Anna" sort="Zecchinelli, Anna" uniqKey="Zecchinelli A" first="Anna" last="Zecchinelli">Anna Zecchinelli</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mariani, Claudio B" sort="Mariani, Claudio B" uniqKey="Mariani C" first="Claudio B." last="Mariani">Claudio B. Mariani</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author><author><name sortKey="Pezzoli, Gianni" sort="Pezzoli, Gianni" uniqKey="Pezzoli G" first="Gianni" last="Pezzoli">Gianni Pezzoli</name><affiliation><mods:affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-09">2000-09</date><biblScope unit="volume">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="986">986</biblScope><biblScope unit="page" to="989">989</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</idno><idno type="DOI">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</idno><idno type="ArticleID">MDS1034</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Depression</term><term>Parkinson's</term><term>Paroxetine</term><term>SSRI</term><term>Safety</term><term>Tolerability</term><term>disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Silvana Tesei MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Angelo Antonini MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Margherita Canesi MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Anna Zecchinelli MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Claudio B. Mariani MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item><json:item><name>Gianni Pezzoli MD</name><affiliations><json:string>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>SSRI</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Paroxetine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Safety</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Tolerability</value></json:item></subject><articleId><json:string>MDS1034</json:string></articleId><language><json:string>eng</json:string></language><abstract>Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p >0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</abstract><qualityIndicators><score>3.923</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>7</keywordCount><abstractCharCount>1006</abstractCharCount><pdfWordCount>2027</pdfWordCount><pdfCharCount>12993</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>158</abstractWordCount></qualityIndicators><title>Tolerability of paroxetine in Parkinson's disease: A prospective study</title><genre><json:string>brief communication</json:string></genre><host><volume>15</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>989</last><first>986</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1002/1531-8257(200009)15:5>986::AID-MDS1034>3.0.CO;2-I</json:string></doi><id>866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2000</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title><author><persName><forename type="first">Silvana</forename><surname>Tesei</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Angelo</forename><surname>Antonini</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neuroscience, Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126 Milan, Italy</p></note><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Margherita</forename><surname>Canesi</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Anna</forename><surname>Zecchinelli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Claudio B.</forename><surname>Mariani</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author><author><persName><forename type="first">Gianni</forename><surname>Pezzoli</surname></persName><roleName type="degree">MD</roleName><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2000-09"></date><biblScope unit="volume">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="986">986</biblScope><biblScope unit="page" to="989">989</biblScope></imprint></monogr><idno type="istex">866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</idno><idno type="DOI">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</idno><idno type="ArticleID">MDS1034</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Depression</term></item><item><term>Parkinson's</term></item><item><term>disease</term></item><item><term>SSRI</term></item><item><term>Paroxetine</term></item><item><term>Safety</term></item><item><term>Tolerability</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-08-31">Received</change><change when="2000-04-04">Registration</change><change when="2000-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/866417BCF8933A1A097A3C9EC708B2D1E9EFB85F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/1531-8257(200009)15:5<>1.0.CO;2-S</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2000-09">September 2000</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="34" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</doi><idGroup><id type="unit" value="MDS1034"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2000 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-08-31"></event><event type="manuscriptRevised" date="2000-03-23"></event><event type="manuscriptAccepted" date="2000-04-04"></event><event type="firstOnline" date="2001-01-23"></event><event type="publishedOnlineFinalForm" date="2001-01-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.18.1 mode:FullText source:HeaderRef result:HeaderRef" date="2010-09-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">986</numbering><numbering type="pageLast">989</numbering></numberingGroup><correspondenceTo>Department of Neuroscience, Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126 Milan, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1034.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="12"></count><count type="wordTotal" number="2141"></count></countGroup><titleGroup><title type="main" xml:lang="en">Tolerability of paroxetine in Parkinson's disease: A prospective study</title><title type="short" xml:lang="en">Tolerability of Paroxetine in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Silvana</givenNames><familyName>Tesei</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Angelo</givenNames><familyName>Antonini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Margherita</givenNames><familyName>Canesi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anna</givenNames><familyName>Zecchinelli</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Claudio B.</givenNames><familyName>Mariani</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gianni</givenNames><familyName>Pezzoli</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Depression</keyword><keyword xml:id="kwd2">Parkinson's</keyword><keyword xml:id="kwd3">disease</keyword><keyword xml:id="kwd4">SSRI</keyword><keyword xml:id="kwd5">Paroxetine</keyword><keyword xml:id="kwd6">Safety</keyword><keyword xml:id="kwd7">Tolerability</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Tolerability of paroxetine in Parkinson's disease: A prospective study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Tolerability of Paroxetine in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Tolerability of paroxetine in Parkinson's disease: A prospective study</title></titleInfo><name type="personal"><namePart type="given">Silvana</namePart><namePart type="family">Tesei</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angelo</namePart><namePart type="family">Antonini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><description>Correspondence: Department of Neuroscience, Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Via Bignami, 1, 20126 Milan, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Margherita</namePart><namePart type="family">Canesi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anna</namePart><namePart type="family">Zecchinelli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudio B.</namePart><namePart type="family">Mariani</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gianni</namePart><namePart type="family">Pezzoli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson Center, Department of Neuroscience, Istituti Clinici di Perfezionamento, Milan, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief communication" displayLabel="shortCommunication"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2000-09</dateIssued><dateCaptured encoding="w3cdtf">1999-08-31</dateCaptured><dateValid encoding="w3cdtf">2000-04-04</dateValid><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">12</extent><extent unit="words">2141</extent></physicalDescription><abstract lang="en">Depression is a common finding in patients with Parkinson's disease (PD). Traditionally, depression has been treated with tricyclic antidepressants, which are often associated with undesirable side effects that may limit their use in PD. Few studies have been performed with selective serotonin reuptake inhibitors (SSRIs) in these patients. We assessed the tolerability of the SSRI antidepressant paroxetine (10–20 mg once per day) in 65 outpatients with PD and depression for a period of at least 3 months. Treatment was continued for 125.3 ± 89.6 days (mean ± standard deviation) in 52 patients. In these subjects the Hamilton Disease Rating Scale improved from 21.7 ± 6.4 to 13.8 ± 5.8 (p <0.001). Overall, 13 patients stopped paroxetine after 9.6 ± 10.6 days because of adverse reactions. Two patients reported increased “off” time and tremor that reversed after treatment was stopped. No risk factors for intolerance were identified. Paroxetine is a safe and effective drug to treat depression in PD.</abstract><subject lang="en"><genre>Keywords</genre><topic>Depression</topic><topic>Parkinson's</topic><topic>disease</topic><topic>SSRI</topic><topic>Paroxetine</topic><topic>Safety</topic><topic>Tolerability</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>986</start><end>989</end><total>4</total></extent></part></relatedItem><identifier type="istex">866417BCF8933A1A097A3C9EC708B2D1E9EFB85F</identifier><identifier type="DOI">10.1002/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I</identifier><identifier type="ArticleID">MDS1034</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2000 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002A02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:866417BCF8933A1A097A3C9EC708B2D1E9EFB85F
|texte= Tolerability of paroxetine in Parkinson's disease: A prospective study
}}
| This area was generated with Dilib version V0.6.23. |  |